News

Communique #72

27 September, 2022

Click for the latest Taskforce news: 

Communique

Communique #71

16 September, 2022

Click for the latest Taskforce news: 

Communique

Meet the Evidence Team: Annie Synnot

5 August, 2022

Read our Q&A with Annie Synnot, Consumer Panel Methods Chair: Introduce yourself and your role with the Taskforce/Consumer Panel. Hi, I’m Annie Synnot and I’m based in Adelaide....

News

Communique #67

7 July, 2022

Click for the latest Taskforce news: 

Communique

Communique #62

31 March, 2022

Click for the latest Taskforce news:   

Communique

Communique #60

17 March, 2022

Click for the latest Taskforce news: 

Communique

Consumer Panel Recruitment

10 March, 2022

Would you like to use your experience to improve the care of Australians with COVID-19? The National COVID-19 Clinical Evidence Taskforce is seeking two new members to join...

News

Communique #44

24 May, 2021

WEEK IN REVIEW UPDATES TO THE LIVING GUIDELINE New recommendations Baricitinib upgraded to a conditional recommendation The Disease-Modifying Treatment and Chemoprophylaxis Panel has reviewed the latest evidence for...

Communique

Communique #43

10 May, 2021

WEEK IN REVIEW Taskforce reaches consensus on first IPC recommendations On Monday 03 May, the Taskforce provided the Infection Control Expert Group (ICEG) with the final draft of the...

Communique

🎥 WEBINAR: Living Evidence, COVID-19 and consumers?

4 May, 2021

Learn how the Taskforce develops living guideline recommendations and the role of consumers If you missed the recent webinar hosted by Consumers Health Forum of Australia, you can...

Video

Webinar: Living Evidence and consumers

22 April, 2021

Are you interested in developing a better understanding of how clinical guidelines can be kept up-to-date with the latest evidence as new research emerges? The Taskforce is proud...

News

Communique #40

18 March, 2021

WEEK IN REVIEW UPDATES TO THE LIVING GUIDELINE New recommendation for tocilizumab in children or adolescents Further to the Taskforce's recent recommendation for the conditional use of tocilizumab for adults (25...

Communique

Seeking consumers and carers with lived experience of COVID-19

24 February, 2021

Share your lived experiences of COVID-19 and contribute to the national guidelines The Taskforce welcomes people who have been affected by COVID-19 to join the Consumer Panel.  The...

News

Weekly Communique #34

3 December, 2020

WEEK IN REVIEW Updates to the living guideline New recommendations published this week cover: Dutasteride Oestrogen-containing therapies (including menopause hormone therapies (MHT) and contraceptives). These recommendations were developed by the...

Communique

Weekly Communique #30

5 November, 2020

WEEK IN REVIEW Bromhexine hydrochloride added to list of 'only in clinical trials' The Disease-Modifying Treatment and Chemoprophylaxis Panel has reviewed two new trial results for bromhexine hydrochloride (commonly...

Communique

Weekly Communique #24

24 September, 2020

WEEK IN REVIEW Six-month milestone for the Taskforce There was great anxiety among clinicians back in March, as Australia prepared to face the first wave of the COVID-19 pandemic and the...

Communique

Weekly Communique #15

23 July, 2020

WEEK IN REVIEW Rooming-in recommendation The Pregnancy and Perinatal Care Panel have made their third conditional recommendation. This week's concerns Rooming-in: For women with COVID-19 who have given birth,...

Communique

Weekly Communique #14

16 July, 2020

WEEK IN REVIEW This week we experienced a shift in the level of alert among the clinicians who form Australia's frontline healthcare response to COVID-19, particularly in Victoria....

Communique

Weekly Communique #9

11 June, 2020

WEEK IN REVIEW Time to acknowledge our expert volunteer contributions It's hard to believe that it's been 12 weeks since the Taskforce's first panel meeting. What began with...

Communique

Weekly Communique #7

28 May, 2020

WEEK IN REVIEW The Taskforce has issued a consensus recommendation to consider increased-dose venous thromboembolism (VTE) prophylaxis for adults with severe to critical COVID-19. This recommendation was developed with input from thrombosis specialists on the Taskforce's...

Communique